Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis
Alberto Gajofatto(University of Verona), Emmanuelle Waubant(University of California, San Francisco), Barbara Grimes(University of California, San Francisco), Peter Bacchetti(University of California, San Francisco), A. High(University of California, San Francisco)
Cited by 98
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival
|Hepatology|2001|2.3k
Age Affects Outcomes in Chronic Kidney Disease
|Journal of the American Society of Nephrology|2007|749